Affiliations 

  • 1 Department of Pharmacy, Putrajaya Hospital, Precinct 7, Putrajaya, 62250, Malaysia
  • 2 Faculty of Pharmacy, University of Malaya, Kuala Lumpur, 50603, Malaysia
  • 3 Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia
  • 4 Department of Medicine, Putrajaya Hospital, Precinct 7, Putrajaya, 62250, Malaysia
Pharmacogenomics, 2021 11;22(16):1057-1068.
PMID: 34665019 DOI: 10.2217/pgs-2021-0059

Abstract

Aim: This study investigated the incidence of sulfonylurea-induced hypoglycemia and its predictors in Type 2 diabetes (T2D) patients. Patients & methods: In this prospective, observational study, T2D patients on maximal sulfonylurea-metformin therapy >1 year were enrolled. Hypoglycemia was defined as having symptoms or a blood glucose level <3.9 mmol/l. Results: Of the 401 patients, 120 (29.9%) developed sulfonylurea-induced hypoglycemia during the 12-month follow-up. The ABCC8 rs757110, KCNJ11 rs5219, CDKAL1 rs7756992 and KCNQ1 rs2237892 gene polymorphisms were not associated with sulfonylurea-induced hypoglycemia (p > 0.05). Prior history of hypoglycemia admission (odds ratio = 16.44; 95% CI: 1.74-154.33, p = 0.014) independently predicted its risk. Conclusion: Sulfonylurea-treated T2D patients who experienced severe hypoglycemia are at increased risk of future hypoglycemia episodes.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.